Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that the rintatolimod European early access program (EAP) designed to enable access of the compound to ME/CFS patients has been extended to pancreatic cancer patients beginning in the Netherlands. The first patient was dosed and several other patients are in the queue to receive rintatolimod. MyTomorrows, Hemispherx’ exclusive service provider in Europe and Turkey, will manage all EAP activities relating to the extension in addition to its existing activities regarding early access use in chronic fatigue syndrome patients.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a3000d23-80f5-4385-b6c8-a96139c9bec6“Pancreatic cancer patients generally have a poor prognosis and few therapeutic options. The cancer is commonly diagnosed at an advanced stage with a five-year survival rate of roughly only seven percent for all pancreatic cancer patients,” said Thomas Equels, CEO of Hemispherx, “We are happy to be able to expand our EAP to a patient population for this devastating malignancy with such a clearly unmet medical need.” 
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection^® and the experimental therapeutics Rintatolimod^® (tradenames Ampligen^® or Rintamod^®) and Alferon^® LDO. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Rintatolimod and Alferon^® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection^®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon N Injection^® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company’s Alferon N^® approval in Argentina includes the use of Alferon N Injection^® (under the pending brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. Rintamod^® has received approval in the Argentine Republic to treat severe cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It will be marketed by GP Pharm, Hemispherx’s commercial partner in Latin America. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.